Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER: Oral 5-aminolevulinic acid to prevent urinary adverse events after prostate brachytherapy
jRCTs051190077Completed
- Sponsor
- SBI Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of aminolevulinic acid in prostate cancer (PCa), sponsored by SBI Pharmaceuticals. Primary endpoint: Urinary frequency at 3 months after low-dose rate brachytherapy. Started Dec 2019; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs051190077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190077.